ERBB2 and neoplasm: Based on our assumptions on the mechanisms of action, our predicted response rate falls within the reported range of response rate of anti-PD-1 monotherapy using pembrolizumab in patients with TNBC or estrogen-positive/HER2-negative metastatic breast cancer (Emens, 2018; Planes-Laine et al., 2019), which demonstrate the ability of the present model to perform virtual clinical trials and make reasonable qualitative predictions on anti-tumor response.